Moderna CEO Stefan Bansel said on Wednesday that his companythe vaccine will not be ready for widespread distribution until next spring, the report said. The drugmaker will also not seek an emergency vaccine permit for first-line health workers and others at risk until November 25, he told the Financial Times.
Speaking at a health conference on Wednesday, Bancel said Moderna would not be ready to seek approval from the Food and Drug Administration for the vaccine for use among the population at least until the end of January. If the vaccine is shown to be safe and effective, approval is unlikely by late March or early April.
“I think it̵
A Moderna spokesman confirmed Bancel’s comment during the conference, noting that the company expects to have enough data on vaccine testing to apply to the FDA for an emergency use permit by November 25th.
Chronology is a failure for Modern, he saidthat he may request an emergency vaccination permit immediately after 1 November. He also struck a chord with President Donald Trump’s claims he reiterated Tuesday in his debate with Joe Biden that the vaccine could be ready in a few weeks or before the November 3 presidential election.
“We have weeks of the vaccine left,” Mr Trump said Tuesday night during the first presidential debate with Biden. Mr Trump’s statement was in response to a question from moderator Chris Wallace about why he disagreed with the leader’s prediction. to the US Centers for Disease Control and Prevention that the vaccine will not be ready until next summer.
“I’ve talked to Pfizer, I’ve talked to all the people you need to talk to – Moderna, Johnson & Johnson and others. They can go much faster than that,” Mr Trump said.
Shares of Moderna fell $ 4 to just over $ 70 a share in news on the revised schedule. Modern did not respond to a request for comment.
Seven potential coronavirus vaccines are now undergoing follow-up testing, although more than 170 potential treatments are under development. About a third of vaccine applicants typically go through the three phases of testing, according to Deutsche Bank analysts.